Ā | Group 1 | Group 2 | Group 3 | Group 4 | ||||
---|---|---|---|---|---|---|---|---|
Tramadol cohort (n=12269) | Naproxen cohort (n=12269) | Tramadol cohort (n=15749) | Diclofenac cohort (n=15749) | Tramadol cohort (n=15410) | Cox-2 inhibitors cohort (n=15410) | Tramadol cohort (n=6751) | Codeine cohort (n=6751) | |
Event (n) | 266 | 227 | 399 | 313 | 377 | 255 | 155 | 180 |
Mean follow-up (years) | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.98 |
Rate, per 1000 PY | 21.7 | 18.5 | 25.3 | 19.9 | 24.5 | 16.6 | 23.0 | 26.7 |
RD (95% CI), per 1000 PY | 3.3 (0.0ā6.7) | 1.0 (ref) | 5.6 (2.3ā9.0) | 1.0 (ref) | 8.1 (4.9ā11.4) | 1.0 (ref) | ā3.8 (ā9.2ā1.5) | 1.0 (ref) |
HR (95% CI) | 1.2 (1.0ā1.4) | 1.0 (ref) | 1.3 (1.1ā1.5) | 1.0 (ref) | 1.5 (1.3ā1.8) | 1.0 (ref) | 0.9 (0.7ā1.1) | 1.0 (ref) |